Payment overview · 2025
General Payments
$2,403.90
147 reported records · 26 companies
Healthcare provider profile · identity verified
Michael L Gross, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · PARAMUS, NJ · NPI 1386701654
Verified facts
What the public records show
CMS Open Payments records show Michael L Gross, MD received $2,403.90 in general payments during 2025 across 147 reported records.
Janssen Biotech, Inc. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kevzara, Otezla, Rinvoq, Tymlos.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kevzara by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Simponi by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Eliquis by this doctor in 2024.
Radius Health, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tymlos as an associated drug or biological on 17199 records involving 7328 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Tymlos by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $393.40 | 16.4% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $364.48 | 15.2% | 39 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $277.73 | 11.6% | 17 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $248.81 | 10.3% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $228.44 | 9.5% | 18 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $104.14 | 4.3% | 6 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $86.14 | 3.6% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.11 | 3.5% | 5 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $81.94 | 3.4% | 5 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $79.28 | 3.3% | 5 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $48.94 | 2.0% | 3 | 2025 |
| DePuy Synthes Sales Inc. | Unresolved — no canonical attribution shown | $44.34 | 1.8% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $39.74 | 1.6% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $39.57 | 1.6% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $36.18 | 1.5% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $36.06 | 1.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $33.94 | 1.4% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $33.85 | 1.4% | 2 | 2025 |
| Alvogen Inc | Unresolved — no canonical attribution shown | $21.66 | 0.9% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $19.40 | 0.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.09 | 0.8% | 1 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $18.71 | 0.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.85 | 0.7% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.75 | 0.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.34 | 0.7% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $15.01 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,214.90 | 145 |
| Education | $189.00 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $393.40 | 13 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $215.09 | 9 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $153.00 | 16 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $137.07 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $117.13 | 9 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $104.14 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $95.24 | 6 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $86.14 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $81.94 | 5 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $78.81 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.41 | 14 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $71.07 | 4 | 2025 |
Source payment records
|
|||||
| SOVUNA Normalized: sovuna |
Drug | ANI Pharmaceuticals, Inc. | $64.84 | 4 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $60.33 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.55 | 13 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $51.35 | 3 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $48.94 | 3 | 2025 |
Source payment records
|
|||||
| MONOVISC Normalized: monovisc |
Device | DePuy Synthes Sales Inc. | $44.34 | 2 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $39.74 | 2 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $39.57 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $36.18 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $35.29 | 2 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $33.85 | 2 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $33.72 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $32.50 | 2 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $31.95 | 2 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Alvogen Inc | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| HYMHYN Normalized: hymhyn |
Device | Fidia Pharma USA Inc. | $19.40 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Monarch Airway Clearance System Normalized: hillrom monarch airway clearance system |
Device | Baxter Healthcare | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $18.08 | 1 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| SPEVIGO Normalized: spevigo |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $14.86 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tymlos tymlos |
2025 | Tymlos | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Radius Health, Inc. Exact reporting entity; no affiliate inference |
2025 | Tymlos open payments reported associated product |
CMS Open Payments — General Payments 17199 supporting records · 7328 recipient NPIs · example record 1249501587 |
Tymlos · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 452 | 115 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 352 | 69 |
| Meloxicam | Meloxicam | 277 | 89 |
| Gabapentin | Gabapentin | 251 | 57 |
| Tramadol Hcl | Tramadol Hcl | 205 | 65 |
| Celecoxib | Celecoxib | 204 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 42 |
| Alprazolam | Alprazolam | 128 | 30 |
| Methotrexate | Methotrexate Sodium | 128 | 33 |
| Colchicine | Colchicine | 113 | 46 |
| Methylprednisolone | Methylprednisolone | 105 | 57 |
| Leflunomide | Leflunomide | 98 | 23 |
| Allopurinol | Allopurinol | 96 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 92 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | 16 |
| Naproxen | Naproxen | 78 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 73 | 19 |
| Omeprazole | Omeprazole | 73 | 24 |
| Furosemide | Furosemide | 72 | 20 |
| Sulfasalazine Dr | Sulfasalazine | 71 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 14 |
| Famotidine | Famotidine | 62 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 60 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 59 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 59 | 16 |
| Diazepam | Diazepam | 58 | 23 |
| Ozempic | Semaglutide | 57 | 13 |
| Lidocaine | Lidocaine | 56 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 55 | 21 |
| Sulfasalazine | Sulfasalazine | 51 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 16 |
| Eliquis | Apixaban | 46 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 46 | 12 |
| Risedronate Sodium | Risedronate Sodium | 46 | 16 |
| Amlodipine Besylate | Amlodipine Besylate | 45 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 44 | 12 |
| Cevimeline Hcl | Cevimeline Hcl | 38 | 13 |
| Modafinil | Modafinil | 38 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Piroxicam | Piroxicam | 37 | 11 |
| Savella | Milnacipran Hcl | 37 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Baclofen | Baclofen | 31 | 17 |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 31 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Tymlos | Abaloparatide | 30 | suppressed |
| Enbrel Sureclick | Etanercept | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 21 |
| Lisinopril | Lisinopril | 26 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 23 | suppressed |
| Nabumetone | Nabumetone | 22 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Edluar | Zolpidem Tartrate | 20 | suppressed |
| Humira(Cf) Pen | Adalimumab | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Simponi | Golimumab | 19 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Losartan Potassium | Losartan Potassium | 17 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 17 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Rinvoq | Upadacitinib | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Carvedilol | Carvedilol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Taltz Autoinjector | Ixekizumab | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | 12 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Chloroquine Phosphate | Chloroquine Phosphate | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Kevzara | Sarilumab | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Metformin Hcl | Metformin Hcl | 11 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,403.90 · 147 records | Janssen Biotech, Inc. | ACTHAR, Actemra, BENLYSTA, Bimzelx, COSENTYX, DUPIXENT, ENBREL, EVENITY, HYMHYN, Hillrom - Monarch Airway Clearance System, ILARIS, INSPIRE, KEVZARA, KRYSTEXXA, LUMRYZ, MONOVISC, NUCALA, NURTEC ODT, OPSUMIT, OTEZLA, PAXLOVID, PEMGARDA, PURIFIED CORTROPHIN GEL, QULIPTA, RINVOQ, SKYRIZI, SOVUNA, SPEVIGO, Sunosi, TAVNEOS, TERIPARATIDE, TONMYA, TRELEGY ELLIPTA, TREMFYA, Tymlos, UBRELVY, VEGZELMA, WAKIX, XELJANZ, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kevzara play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error